BioHarvest Sciences (BHST) investor relations material

Business overview and mission

• Pioneers botanical synthesis, isolating and maximizing plant phyto-nutrients for commercial use by growing only plant cells, not whole plants.

• Mission is to address unmet health and wellness needs with patentable, sustainable plant compounds.

• Over $100M invested in a patented platform over 17 years, with scalable production and a growing product pipeline.

• Focuses on nutraceuticals, cosmetics, pharma/biotech, and nutrition/sweeteners.

Technology and manufacturing

• Proprietary process enables development of next-gen therapeutic compounds with low capital expenditure and high return on capital.

• Only requires a plant once to create perpetual cell banks for ongoing compound production.

• Facilities in Israel support up to 25 metric tons/year, with expansion plans to 100 metric tons and a future US facility.

• Production uses less land, water, and energy than traditional agriculture, supporting sustainability.

Product portfolio and clinical validation

• Flagship product VINIA® is a red grape cell-derived nutraceutical with over $84M in lifetime sales and 85,000+ active users.

• VINIA® is clinically shown to increase arterial dilation by 70%, boost nitric oxide by 120%, and decrease ET-1 by 50%.

• Products are patent-protected, backed by peer-reviewed and scientific studies, and highly rated by consumers.

• Pipeline includes olive and pomegranate cell powders with significantly higher concentrations of key compounds.